支气管哮喘患儿血清25羟维生素D3水平变化及补充维生素D治疗对患儿发病、预后的影响研究

Study on the changes of serum 25-Hydroxyvitamin D3 level in children with bronchial asthma and the effect of vitamin D supplementation on the incidence and prognosis of children

目的探讨分析支气管哮喘患儿血清25羟维生素D3(25-OH-D3)水平变化及补充维生素D治疗对患儿发病、预后的影响。方法回顾性选择2016年1月至2019年1月承德医学院附属医院收治的200例支气管哮喘患儿为研究对象,设为A组,同时选择200例呼吸道感染的非支气管哮喘患儿、200名体检健康儿童分别设为B组与C组。观察比较A、B、C组的血清25-OH-D3水平的差异性;同时将A组患儿随机分为研究组(n=100)与对照组(n=100)。其中对照组予以常规治疗,研究组在对照组基础上予以维生素D治疗。观察比较A、B、C组血清25-OH-D3水平。研究组与对照组患儿治疗前、治疗后3个月血清25-OH-D3水平变化情况,且随访1年,观察比较2组的发作次数、发病严重程度及住院次数。结果A、B、C组血清25-OH-D3水平分别为(20.26±3.75)、(36.98±4.26)、(37.15±4.39)μg/L;A组血清25-OH-D3水平明显低于B组与C组,差异有统计学意义(P<0.05),而B组与C组血清25-OH-D3水平差异无统计学意义(P>0.05)。研究组与对照组治疗前血清25-OH-D3水平[(20.07±3.48)μg/L vs.(20.39±3.78)μg/L]比较,差异无统计学意义(P>0.05);研究组治疗后3个月的血清25-OH-D3水平为(34.28±4.18)μg/L,明显高于对照组的(24.89±3.65)μg/L,差异有统计学意义(P<0.05)。随访1年,研究组的发作次数、住院次数均明显少于对照组[(1.01±0.23)次vs.(2.23±0.54)次、(0.32±0.08)次vs.(1.03±0.24)次](P<0.05),发作重度哮喘/发作次数明显小于对照组[(0.28±0.06)vs.(0.41±0.11)],差异有统计学意义(P<0.05)。结论支气管哮喘患儿的血清25-OH-D3水平明显降低,通过补充维生素D治疗,可明显提高患儿血清25-OH-D3水平,减少发作次数与住院次数,减轻发病时疾病严重程度。

Objective To investigate and analyze the changes of serum 25-hydroxyvitamin D3(25-OH-D3)levels in children with bronchial asthma and the effect of vitamin D supplementation on the onset and prognosis of children.Methods 200 children with bronchial asthma admitted to Affiliated Hospital of Chengde Medical College from January 2016 to January 2019 were selected as the research objects,and set as group A.At the same time,200 children with non-bronchial asthma with respiratory infections and 200 healthy children with physical examination were selected.Set as group B and group C;observe and compare the differences in serum 25-OH-D3 levels in groups A,B,and C;at the same time,children in group A were randomly divided into study group(n=100)and control group(n=100).The control group was given conventional treatment,and the study group was given vitamin D treatment on the basis of the control group.The changes in serum 25-OH-D3 levels before and after treatment were observed and compared between the two groups of children.The number of attacks,the severity of the disease and the number of hospitalizations.Results Serum 25-OH-D3 levels in group A,group B and group C were(20.26±3.75)μg/L,(36.98±4.26)μg/L,(37.15±4.39)μg/L,respectively.The serum 25-OH-D3 level of group A was significantly lower than that of group B and group C,the difference was statistically significant(P<0.05),while the serum 25-OH-D3 level of group B and C had no significant difference(P>0.05).Serum 25-OH-D3 levels before treatment between the study group and the control group were not significantly different[(20.07±3.48)μg/L vs.(20.39±3.78)μg/L](P>0.05);after treatment in the study group,the serum 25-OH-D3 level was(34.28±4.18)μg/L,which was significantly higher than that of the control group(24.89±3.65)μg/L,the difference was statistically significant(P<0.05).Follow-up for 1 year,the number of attacks and hospitalizations in the study group were significantly less than those in the control group[(1.01±0.23)vs.(2.23±0.54),(0.32±0.08)vs.(1.03±0.24)](P<0.05),the number of severe asthma attacks/attack was significantly lower than that of the control group[(0.28±0.06)vs.(0.41±0.11)],the difference was statistically significant(P<0.05).Conclusion The serum 25-OH-D3 level of children with bronchial asthma is significantly reduced.Vitamin D supplementation can significantly increase the serum 25-OH-D3 level of the children,reduce the number of attacks and hospitalizations,and reduce the severity of the disease.